Výsledky vyhledávání - "Arash Y Tehrani"

Akademický článek

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.

Autor: Zoe White, Nadia Milad, Arash Y Tehrani, William Wei-Han Chen, Graham Donen, Stephanie L Sellers, Pascal Bernatchez

Publikováno v: PLoS ONE, Vol 14, Iss 8, p e0220903 (2019)

There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth facto

Externí odkaz: https://doaj.org/article/be524c11a5c04573acfffd11c054bb2a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Waves of calcium depletion in the sarcoplasmic reticulum of vascular smooth muscle cells: an inside view of spatiotemporal Ca2+ regulation.

Autor: Mitra Esfandiarei, Nicola Fameli, Yohan Y H Choi, Arash Y Tehrani, Jeremy G Hoskins, Cornelis van Breemen

Publikováno v: PLoS ONE, Vol 8, Iss 2, p e55333 (2013)

Agonist-stimulated smooth muscle Ca2+ waves regulate blood vessel tone and vasomotion. Previous studies employing cytoplasmic Ca2+ indicators revealed that these Ca2+ waves were stimulated by a combination of inositol 1,4,5-trisphosphate- and Ca2+ -i

Externí odkaz: https://doaj.org/article/69fc7139b44d4c66929211ef7c553a42

Zobrazit plný text záznamu

Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects

Autor: Arash Y, Tehrani, Roy, Zhao, Graham, Donen, Pascal, Bernatchez

Publikováno v: Nitric Oxide. 131:18-25

Low basal nitric oxide (NO) production is associated with a dysfunctional endothelium and vascular diseases. We have shown that some angiotensin II (AngII) receptor type 1 (AT1R) blockers (ARBs), a group of clinic-approved blood pressure (BP)-lowerin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33708a59fda3822bf4390a3a0394925b
https://doi.org/10.1016/j.niox.2022.12.002

Zobrazit plný text záznamu

Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties

Autor: Elodie Sauge, Dmitri Pechkovsky, N.D. Prasad Atmuri, Arash Y. Tehrani, Zoe White, Ying Dong, Jessica Cait, Michael Hughes, Anthony Tam, Graham Donen, Christopher Yuen, Michael J.A. Walker, Kelly M. McNagny, Don D. Sin, Marco A. Ciufolini, Pascal Bernatchez

Publikováno v: Vascular pharmacology. 147

Losartan is an anti-hypertensive angiotensin II (ANGII) type 1 receptor (AT1R) blocker (ARB) with many unexpected therapeutic properties, even in non-blood pressure (BP)-related diseases. Administered as a prodrug, losartan undergoes serial metabolis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a2d6344d86c2b80063c7d3b67b3bbd
https://pubmed.ncbi.nlm.nih.gov/36179789

Zobrazit plný text záznamu

Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects

Autor: Arash Y, Tehrani, Zoe, White, Lin Wei, Tung, Roy Ru Yi, Zhao, Nadia, Milad, Michael A, Seidman, Elodie, Sauge, Marine, Theret, Fabio M V, Rossi, Mitra, Esfandiarei, Casey, van Breemen, Pascal, Bernatchez

Publikováno v: Scientific Reports. 12

There are no therapeutics that directly enhance chronic endothelial nitric oxide (NO) release, which is typically associated with vascular homeostasis. In contrast, angiotensin II (AngII) receptor type 1 (AT1R) blockers (ARBs) can attenuate AngII-med

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8526d492b1822e202ef1ec41ba807424
https://doi.org/10.1038/s41598-022-13772-3

Zobrazit plný text záznamu

Nitric oxide in the Marfan vasculature: Friend or foe?

Autor: Marco A. Ciufolini, Pascal Bernatchez, Arash Y. Tehrani

Publikováno v: Nitric oxide : biology and chemistry. 116

Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the FBN1 gene, which encodes fibrillin-1, a protein essential for the formation and stabilization of elastic fibers as well as signaling homeostasis. Progressive aortic root

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a8e8c1ecefe62e5b22c08005861ced
https://pubmed.ncbi.nlm.nih.gov/34478846

Zobrazit plný text záznamu

Blood pressure‐independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan

Autor: Pascal Bernatchez, Mitra Esfandiarei, Michael A. Seidman, Nadia Milad, Zoe White, Arash Y. Tehrani

Publikováno v: Physiological Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
Physiological Reports

Marfan syndrome (MFS) is a genetic disorder that results in accelerated aortic root widening and aneurysm. However, management of MFS patients with blood pressure (BP)‐lowering medications, such as angiotensin II (AngII) receptor blocker (ARB) losa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abee53b5f9de3d07e9f8485c539e452a
https://doaj.org/article/e479c412085d46fe8795042de6d00b01

Zobrazit plný text záznamu

Plný text ve formátu HTML

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B

Autor: Pascal Bernatchez, Stephanie L. Sellers, William Wei-Han Chen, Nadia Milad, Zoe White, Arash Y. Tehrani, Graham Donen

Publikováno v: PLoS ONE, Vol 14, Iss 8, p e0220903 (2019)
PLoS ONE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68185d6f7c6bbeb39d403b9b5e7c973e
https://doaj.org/article/be524c11a5c04573acfffd11c054bb2a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání